Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Nordic biotech company Pila Pharma, founded and chaired by former Novo Nordisk researcher Dorte X. Gram, has recently raised 10 million SEK in directed issue for a novel obesity-related study.An ...

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Ozempic maker Novo Nordisk has developed a pill that can cause weight loss of up to 13% in three months, according to new ...

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...